[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biochemically-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biochemically-recurrent":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053604","prospective-monitoring-of-subjects-with-biochemically-recurrent-prostate-cancer-using-18fdcfpyl-100053604",false,"NCT05588128","Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL","A Study of Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL","* INCLUSION CRITERIA:\n* History of primary treatment for prostate cancer (either surgery or radiation)\n* Serum PSA \\>= 0.50\n* Serum testosterone \\>100\n* Age \\>=18 years\n* Men must agree to use highly effective contraception (surgical sterilization) for 7 days after every study agent administration. Note: abstinence, defined as no heterosexual sexual intercourse when this is in line with the preferred and usual lifestyle of the subject is also acceptable\n* The ability of a participant to understand and the willingness to sign a written informed consent document\n\nEXCLUSION CRITERIA:\n\n-Evidence of soft tissue disease on CT scan (or magnetic resonance imaging \\[MRI\\] as clinically indicated).\n\nNOTE: Lymph nodes \\\u003C= 1.5 cm in the shortest dimension are allowed.\n\n* Evidence of bone lesions on Tc99 bone scan\n* Prostatectomy within 1 year before the study intervention\n* Androgen deprivation therapy (ADT) within the 6 months before the study intervention\n* Systemic therapy for prostate cancer within the 6 months before the study intervention. Other investigational agents, excluding those involving standard of care chemotherapy, received within 6 months prior to the study intervention are allowed.","MALE","18 Years",{"count":19,"type":20},350,"ESTIMATED","OBSERVATIONAL","Background:\n\nProstate cancer is the second leading cause of cancer-related death in American men. The disease recurs in up to 50,000 men each year after their early-stage disease was treated; however, at this stage, imaging scans are often unable to find the disease in the body. In this natural history study, researchers want to find out if a new radiotracer (18F-DCFPyL) injected before positron emission tomography (PET) imaging can help identify sites in the body with cancer.\n\nObjective:\n\nTo learn more about how 18F-DCFPyL PET\u002FCT scans detect change over time in men with recurrent prostate cancer.\n\nEligibility:\n\nMen aged 18 and older with prostate cancer that returned after treatment.\n\nDesign:\n\nParticipants will be screened with blood tests. They will also have a bone scan and a computed tomography (CT) scans of the chest, abdomen, and pelvis.\n\nParticipants will have an initial study visit. They will have a physical exam and blood tests. They will have a PET\u002FCT scan with 18F-DCFPyL. The radiotracer will be injected into a vein; this will take about 20 seconds. The PET\u002FCT scan will be done 1 to 2 hours later. Participants will lie still on a scanner table while a machine captures images of their body. The scan will take 45 minutes.\n\nParticipants will return for blood tests every 3 months.\n\nParticipants will return for additional scans with 18F-DCFPyL on this schedule:\n\nOnce a year if their previous scan was negative for prostate cancer.\n\nEvery 6 months if their previous scan was positive for prostate cancer.\n\nParticipants may be in the study up to 5 years.",[24,25],"Prostate Cancer","Biochemically Recurrent",[27,28,29],"Cancer Of Prostate","Natural History","Imaging","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2023-03-21",{"date":38,"type":20},"2027-12-31",{"name":40,"class":41},"National Cancer Institute (NCI)","NIH",1,{"id":44,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":46,"keywords":47,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":51,"completionDateStruct":52,"leadSponsor":53,"locationsCount":42},"100484444",{"count":19,"type":20},[24,25],[27,28,29],"2026-06-27",{"date":50,"type":34},"2026-06-30",{"date":36,"type":34},{"date":38,"type":20},{"name":40,"class":41}]